Search Results

QIAGEN announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret, that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing labs moving to larger test panels and higher test volumes.

QIAGEN announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus.

QIAGEN announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of hereditary and somatic diseases, has received the European Union Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation 2017/746.

QIAGEN will announce at its Capital Markets Day a commitment to deliver solid profitable growth through 2028 – led by about 7% compound annual sales growth at constant exchange rates during the four-year period and achieving at least a 31% CER adjusted operating income margin in 2028.

QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States.

QIAGEN announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR platform QIAcuity, significantly enhancing its offerings in the field of microbial research.

QIAGEN announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.

QIAGEN N.V. announced plans to release results for the first quarter 2024.

QIAGEN announced that the U.S. Food and Drug Administration has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.